Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:CADL NASDAQ:DTIL NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$7.01-0.6%$6.97$4.73▼$9.53$728.88M0.4507,005 shs481,235 shsCADLCandel Therapeutics$9.40-2.9%$9.13$4.35▼$11.36$709.26M-0.521.29 million shs1.44 million shsDTILPrecision BioSciences$6.89-3.9%$7.36$3.53▼$9.62$185M1.25464,946 shs301,618 shsMNPRMonopar Therapeutics$107.43-1.5%$83.51$29.18▼$116.64$730.80M1.46248,612 shs357,180 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-0.57%0.00%+1.89%-0.57%+3.24%CADLCandel Therapeutics-2.89%-6.84%-9.27%+52.10%+43.07%DTILPrecision BioSciences-3.91%-5.87%-13.01%-3.64%+40.90%MNPRMonopar Therapeutics-1.52%-4.49%+13.61%+106.00%+149.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$7.01-0.6%$6.97$4.73▼$9.53$728.88M0.4507,005 shs481,235 shsCADLCandel Therapeutics$9.40-2.9%$9.13$4.35▼$11.36$709.26M-0.521.29 million shs1.44 million shsDTILPrecision BioSciences$6.89-3.9%$7.36$3.53▼$9.62$185M1.25464,946 shs301,618 shsMNPRMonopar Therapeutics$107.43-1.5%$83.51$29.18▼$116.64$730.80M1.46248,612 shs357,180 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-0.57%0.00%+1.89%-0.57%+3.24%CADLCandel Therapeutics-2.89%-6.84%-9.27%+52.10%+43.07%DTILPrecision BioSciences-3.91%-5.87%-13.01%-3.64%+40.90%MNPRMonopar Therapeutics-1.52%-4.49%+13.61%+106.00%+149.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.25Hold$20.50192.44% UpsideCADLCandel Therapeutics 2.60Moderate Buy$18.5797.57% UpsideDTILPrecision BioSciences 2.60Moderate Buy$32.25368.07% UpsideMNPRMonopar Therapeutics 3.07Buy$112.084.33% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, MNPR, AURA, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2026CADLCandel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.007/23/2026MNPRMonopar Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$125.007/22/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$105.00 ➝ $125.007/17/2026CADLCandel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026MNPRMonopar Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/14/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026CADLCandel Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.007/13/2026MNPRMonopar Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/9/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026MNPRMonopar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$104.00 ➝ $117.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ACADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ADTILPrecision BioSciences$34.26M5.19N/AN/A$4.03 per share1.71MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)CADLCandel Therapeutics-$38.18M-$0.98N/AN/AN/AN/A-60.42%-41.33%8/13/2026 (Estimated)DTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)Latest DTIL, MNPR, AURA, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026CADLCandel Therapeutics-$0.22N/AN/AN/AN/AN/A8/12/2026Q2 2026AURAAura Biosciences-$0.41N/AN/AN/AN/AN/A8/11/2026Q2 2026MNPRMonopar Therapeutics-$0.67N/AN/AN/AN/AN/A8/6/2026Q2 2026DTILPrecision BioSciences-$0.71N/AN/AN/A$1.40 millionN/A5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/14/2026Q1 2026CADLCandel Therapeutics-$0.2958-$0.14+$0.1558-$0.14N/AN/A5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09CADLCandel Therapeutics0.3428.0528.05DTILPrecision BioSciences0.2914.0214.02MNPRMonopar TherapeuticsN/A56.0456.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%CADLCandel Therapeutics13.93%DTILPrecision BioSciences37.99%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences1.90%CADLCandel Therapeutics14.30%DTILPrecision BioSciences2.70%MNPRMonopar Therapeutics9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences50103.39 million101.42 millionNot OptionableCADLCandel Therapeutics6073.27 million62.79 millionOptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableDTIL, MNPR, AURA, and CADL HeadlinesRecent News About These CompaniesMonopar Therapeutics Inc. $MNPR Position Increased by ADAR1 Capital Management LLCJuly 29 at 3:03 AM | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of "Buy" by AnalystsJuly 28 at 2:14 AM | americanbankingnews.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from AnalystsJuly 28 at 2:13 AM | marketbeat.comEquities Analysts Offer Predictions for MNPR FY2027 EarningsJuly 26, 2026 | americanbankingnews.comHC Wainwright Has Positive Outlook of MNPR FY2027 EarningsJuly 24, 2026 | marketbeat.comSiren L.L.C. Increases Stake in Monopar Therapeutics Inc. $MNPRJuly 24, 2026 | marketbeat.comWalleye Capital LLC Takes Position in Monopar Therapeutics Inc. $MNPRJuly 24, 2026 | marketbeat.comHC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $125.00July 24, 2026 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Stock Price Down 8.9% - What's Next?July 23, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock PriceJuly 22, 2026 | marketbeat.comMonopar Initiates Rolling NDA Submission for ALXN1840 in Wilson DiseaseJuly 22, 2026 | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Sets New 12-Month High - What's Next?July 20, 2026 | marketbeat.comMonopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership TeamJuly 20, 2026 | globenewswire.comMonopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)July 17, 2026 | seekingalpha.comMonopar Therapeutics (NASDAQ:MNPR) Shares Up 6.8% - What's Next?July 15, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Upgraded at Zacks ResearchJuly 15, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Lowered to "Sell" Rating by Wall Street ZenJuly 12, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Hits New 12-Month High - Here's WhyJuly 9, 2026 | marketbeat.comMonopar Therapeutics: ALXN1840's Bull Case Has ImprovedJuly 3, 2026 | seekingalpha.comMonopar Wins FDA Rare Pediatric Disease DesignationJuly 1, 2026 | theglobeandmail.comMonopar Therapeutics Inc (MNPR) Gets a Buy from Lake StreetJuly 1, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Confidence Is Back, But Earnings Show the Consumer Is Being PickyBy Jessica Mitacek | July 21, 2026Burger King’s Turnaround Is Putting Restaurant Brands Back in FocusBy Peter Frank | July 1, 2026Toast’s Comeback Story Is Getting Harder for Wall Street to IgnoreBy Chris Markoch | July 16, 2026Is Domino's Stock Serving Up a Buying Opportunity?By Jeffrey Neal Johnson | July 20, 2026DTIL, MNPR, AURA, and CADL Company DescriptionsAura Biosciences NASDAQ:AURA$7.01 -0.04 (-0.57%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$6.99 -0.02 (-0.23%) As of 07/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Candel Therapeutics NASDAQ:CADL$9.40 -0.28 (-2.89%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$9.59 +0.19 (+2.02%) As of 07/29/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Precision BioSciences NASDAQ:DTIL$6.89 -0.28 (-3.91%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$6.92 +0.03 (+0.49%) As of 07/29/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Monopar Therapeutics NASDAQ:MNPR$107.43 -1.66 (-1.52%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$106.82 -0.62 (-0.57%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
